Studies supporting an investigational new drug (IND) application for X-165, a potential candidate for the treatment of idiopathic pulmonary fibrosis (IPF) and other fibrotic disorders, have been completed, X-Rx recently announced. According to the U.S. Food and Drug Administration, an IND application permits the manufacturer to transport…
News
Combining Ofev (nintedanib, marketed by Boehringer Ingelheim) with sildenafil does not offer additional clinical benefits when compared to Ofev treatment alone regarding quality of life and lung function in patients with idiopathic…
Veracyte will present new results that showcase the ability of the Envisia Genomic Classifier to provide reliable data that helps physicians diagnose interstitial lung disease (ILD) — including idiopathic pulmonary fibrosis (IPF) — at CHEST 2018 meeting. Veracyte also will present new results about the capability of the…
A recent study in mice shows that endometrial regenerative cells (ERCs) can ease some of the common symptoms of idiopathic pulmonary fibrosis (IPF). Titled “Human Endometrial Regenerative Cells Attenuate Bleomycin-Induced Pulmonary Fibrosis in Mice,” the study was recently published in the journal Stem Cells International. Therapeutic…
Treatment with Esbriet (pirfenidone) or Ofev (nintedanib) significantly slowed the progression of idiopathic pulmonary fibrosis (IPF) in a real-life clinical setting, an Italian study reported. The study, “Pirfenidone and Nintedanib in idiopathic pulmonary fibrosis: Real-life experience in an Italian referral centre” was published in the journal…
Samumed and United Therapeutics announced an exclusive license agreement for North American rights to Samumed’s investigational therapy SM04646 to treat idiopathic pulmonary fibrosis (IPF). Under the agreement, United Therapeutics will pay Samumed $10 million up-front, plus up to $340 million in developmental milestones in addition to other…
Corbus Pharmaceuticals has acquired from Jenrin Discovery more than 600 compounds designed to target the endocannabinoid system, including CRB-4001 for the treatment of fibrotic diseases affecting the lungs, liver, heart, and kidney. The endocannabinoid system is associated with the resolution (or shutting off) of the inflammatory response, which…
Roivant Sciences has launched a new company whose focus is developing potential treatments for serious respiratory diseases. Named Respivant Sciences, it will begin by advancing RVT-1601 as an investigative therapy for chronic cough in patients with idiopathic pulmonary fibrosis (IPF). RVT-1601, formerly known as PA101, is a novel formulation…
More than 700 medical experts, pharmaceutical executives, patient advocates, and others are expected to converge on Washington, D.C., next month for the 2018 NORD Rare Diseases & Orphan Products Breakthrough Summit. The Oct. 15-16 event, sponsored by the National Organization for Rare Diseases (NORD), takes place at the…
Long-term treatment with Ofev (nintedanib) can safely slow disease progression in people with idiopathic pulmonary fibrosis (IPF), new four-year data from INPULSIS-ON, an open-label Phase 3 extension trial, show. The findings were reported in “Long-term safety and tolerability of nintedanib in patients with idiopathic pulmonary fibrosis: results from…
